JO
CHRS icon

John Overdeck’s Coherus Oncology CHRS Stock Holding History

John Overdeck’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16M Sell
2,259,412
-42,589
-2% -$69.5K ﹤0.01% 2572
2026
Q1 		$3.89M Buy
2,302,001
+1,798,126
+357% +$3.19M ﹤0.01% 2201
2025
Q4 		$716K Buy
503,875
+468,163
+1,311% +$682K ﹤0.01% 3123
2025
Q3 		$58.6K Buy
+35,712
New +$39.7K ﹤0.01% 3526
2025
Q1 		– Sell
-134,138
Closed -$185K – 3239
2024
Q4 		$185K Sell
134,138
-548,242
-80% -$615K ﹤0.01% 2887
2024
Q3 		$710K Sell
682,380
-151,861
-18% -$208K ﹤0.01% 2298
2024
Q2 		$1.44M Sell
834,241
-627,772
-43% -$1.26M ﹤0.01% 1776
2024
Q1 		$3.49M Buy
1,462,013
+11,661
+0.8% +$28.7K 0.01% 1166
2023
Q4 		$4.83M Buy
+1,450,352
New +$3.88M 0.01% 1015
2023
Q2 		– Sell
-23,100
Closed -$158K – 3040
2023
Q1 		$158K Sell
23,100
-96,769
-81% -$751K ﹤0.01% 2605
2022
Q4 		$949K Sell
119,869
-249,914
-68% -$1.92M ﹤0.01% 1722
2022
Q3 		$3.55M Buy
369,783
+351,205
+1,890% +$3.55M 0.01% 890
2022
Q2 		$135K Buy
+18,578
New +$162K ﹤0.01% 2231
2022
Q1 		– Sell
-15,600
Closed -$249K – 2913
2021
Q4 		$249K Buy
+15,600
New +$273K ﹤0.01% 3774
2021
Q2 		– Sell
-98,160
Closed -$1.43M – 4094
2021
Q1 		$1.43M Buy
+98,160
New +$1.67M ﹤0.01% 1987
2020
Q2 		– Sell
-157,591
Closed -$2.56M – 2998
2020
Q1 		$2.56M Sell
157,591
-496,281
-76% -$9.17M 0.02% 838
2019
Q4 		$11.8M Buy
653,872
+563,679
+625% +$10.4M 0.04% 554
2019
Q3 		$1.83M Sell
90,193
-69,666
-44% -$1.39M 0.01% 1512
2019
Q2 		$3.53M Buy
159,859
+117,712
+279% +$2.04M 0.01% 1081
2019
Q1 		$575K Sell
42,147
-191,958
-82% -$2.56M ﹤0.01% 2187
2018
Q4 		$2.12M Buy
234,105
+74,690
+47% +$864K 0.01% 1213
2018
Q3 		$2.63M Sell
159,415
-15,657
-9% -$278K 0.01% 1292
2018
Q2 		$2.45M Buy
+175,072
New +$2.51M 0.01% 1478
2017
Q1 		– Sell
-115,480
Closed -$3.25M – 2940
2016
Q4 		$3.25M Buy
+115,480
New +$3.23M 0.01% 1128

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

John Overdeck's CHRS Position: Q2 2026 in Review

John Overdeck reduced its Coherus Oncology (CHRS) stake by 1.9% in Q2 2026, selling an estimated $69.5K and leaving 2,259,412 shares worth $3.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2572.

John Overdeck first reported a position in CHRS in Q4 2016 and has held it in 24 quarters since. The position peaked at $11.8M in Q4 2019. 145 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • John Overdeck held 2,259,412 shares of Coherus Oncology worth $3.16M as of Q2 2026.
  • John Overdeck sold 42,589 Coherus Oncology shares in Q2 2026, an estimated $69.5K.
  • Coherus Oncology made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2572 holding.
  • John Overdeck first reported a position in Coherus Oncology in Q4 2016 and has held it in 24 quarters since.
  • John Overdeck's Coherus Oncology position peaked at $11.8M in Q4 2019.
  • 145 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.